MiroBio: MiroBio's $97 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal. MiroBio, a leader in the development of checkpoint agonists to treat autoimmune diseases, announced the completion [...]
Read full article »
MiroBio is an England-based biotechnology company that develops and commercializes novel therapeutics for the treatment of auto-immune diseases.
Read more